Treatment is determined by what is causing your kidneys to not function normally. Treating the cause is key, leading to reduced complications and slowing progression of kidney disease. For example, getting better blood pressure control, improved sugar control and diabetes, and reducing weight are often key interventions. However, existing damage is not usually reversible. In some conditions, treatment can reverse the cause of the disease. So seeking medical review is really important. Individual complications vary, but treatment might include high blood pressure medication, diuretics to reduce fluid and swelling, supplements to relieve anemia, statins to lower cholesterol, or medications to protect your bones and prevent blood vessel calcification. A lower-protein diet may also be recommended. It reduces the amount of waste your kidneys need to filter from your blood. These can not only slow the damage of kidney disease, but make you feel better as well. When the damage has progressed to the point that 85 to 90 percent of your kidney function is gone, and they no longer work well enough to keep you alive, it's called end-stage kidney failure. But there are still options. There's dialysis, which uses a machine to filter the toxins and remove water from your body as your kidneys are no longer able to do this. Where possible, the preferred therapy is a kidney transplant. While an organ transplant can sound daunting, it's actually often the better alternative, and the closest thing to a cure, if you qualify for a kidney transplant.
The Doctor's Kidney Diets: A Nutritional Guide to Managing and Slowing the Progression of Chronic Ki
Treatment for chronic kidney disease focuses on slowing the progression of kidney damage, usually by controlling the cause. But, even controlling the cause might not keep kidney damage from progressing. Chronic kidney disease can progress to end-stage kidney failure, which is fatal without artificial filtering (dialysis) or a kidney transplant.
Preventing chronic kidney disease (CKD) and its complications is possible by managing risk factors and treating the disease to slow its progression and reduce the risk of complications. To keep healthy kidneys, it is important to control those risk factors for CKD that can be modified.
In stage 3 chronic kidney disease (CKD), the kidneys still function sufficiently to remove fluid, potassium potassium and a moderate amount of waste. In order to help slow the progression of CKD, managing blood pressure, glucose and weight, among other things, is important and can be done through adhering to a kidney diet.
Treatment for a chronic medical condition can slow down the progression of kidney disease. If your kidneys gradually stop working, a healthcare provider may use a few different methods to track your health and maintain kidney function as long as possible. These methods may include:
The effects of high-protein diets (HPDs) on renal health have been investigated since the 1920s when rats given a HPD presented with increased kidney weight [20]. Data suggest that chronic protein intake (more than 1.2 g/kg/body weight/d) [21] leads to increased pressure and glomerular morphologic changes, resulting in renal dysfunction [22]. Glomerular hyperfiltration is defined as modifying renal hemodynamics through glomerular capillary hyperemia and increasing intraglomerular pressure [21]. HPDs induce glomerular hyperfiltration, hyperemia, and increased hydraulic pressure, resulting in vasodilation of the afferent arteriole [22]. HPDs contribute to progressive glomerular damage, which, combined with the renal deterioration from diseased kidneys may contribute to CKD progression. The Modification of Diet in Renal Disease (MDRD) was the largest RCT to examine the hypothesis that dietary protein restriction delays the progression of CKD [PMID 10541304]. The study found proteinuria to be one of the two strongest predictors in the rate of CKD progression in two studies [23]. Oba et al. collected 43 healthy (non-diseased) kidneys from live human donors to examine the effect of an HPD on the single-nephron GFR (SNGFR) [24]. This study concluded that an HPD might increase SNGFR and induce glomerular hyperfiltration; however, this study is unique by identifying that the analysis of human SNGFR is an exemplary parameter to alterations in renal hemodynamics at the single-nephron level [24]. The exact mechanism for renal hemodynamic responses to heightened protein intake is not yet understood [25].
The National Kidney Foundation has developed guidelines for classifying chronic kidney disease based on estimated glomerular filtration rate (eGFR).[6] There are several methods of calculating eGFR. Some are more accurate when predicting a lower GFR while others are better used for estimating GFR in patients without advanced renal disease.[7] The following stages are used to classify abnormal kidney function:
In addition to medication, your NYU Langone doctor may recommend lifestyle changes that can slow the progression of kidney disease. These may include managing underlying conditions, such as diabetes, changing your diet, and exercising. These habits can also help to prevent kidney disease.
Chronic kidney disease occurs mostly in older dogs, as the kidneys lose function over years. While chronic renal failure cannot be reversed or cured, treatment and management aimed at reducing the contributing factors and symptoms can slow its progression.
1. Reutens AT. Epidemiology of Diabetic Kidney Disease. Med Clin North Am. 2013;97:1-18. 2. Grace B, Hurst K, McDonald S. New patients commencing on treatment in 2011. In: The Australia New Zealand dialysis and transplant (ANZDATA) Registry, in the Thirty-fifth Annual Report of the ANZDATA Registry. Adelaide, South Australia: 2012, 10. 3. Praga M, Morales E. obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006;15(5):481-6. 4. Chakkarwar VA. Smoking in diabetic nephropathy: sparks in the fuel tank? World J Diabetes. 2012;3(12):186-95. 5. UK Prospective Diabetes Study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837-53. 6. Agrawal L, Azad N, Emanuele NV, et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011;34:2090-94. 7. UK Prospective Diabetes Study (UKPDS) group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13. 8. Brenner B, Cooper M, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9. 9. de Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-20. 10. Rossing K, Christensen PK, Hovind P, Parving HH. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia. 2005;48:2241-7. 11. Tan J, Jaung R, Gamble G, Cundy T. Proteinuric renal disease in type 2 diabetes - Is remission of proteinuria associated with improved morbidity and mortality? Diab Res Clin Pract. 2014;103:63-7. 12. Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. 13. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542-51. 14. Stewart JH, McCredie MRE, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Mori and Pacific Island people and in Indigenous Australians. Nephrol Dial Transplant. 2004;19(3):678-85. 15. Kenealy T, Elley CR, Collins JF, Moyes SA, et al. Increased prevalence of albuminuria among non-European peoples with type 2 diabetes. Nephrol Dial Transplant. 2012;27:1840-6. 16. Scott A, Toomath R, Bouchier D, et al. First national audit of outcomes of care in young people with diabetes in New Zealand: high prevalence of nephropathy in Mori and Pacific Islanders. N Z Med J. 2006;119(1235):U2015. 17. Hotu C, Bagg W, Collins J, et al. A community-based model of care improves blood pressure control and delays progression of proteinuria, left ventricular hypertrophy and diastolic dysfunction in Mori and Pacific patients with type 2 diabetes and chronic kidney disease: a randomised controlled trial. Nephrol Dial Transplant. 2010;25:3260-6. 18. Russell AW, Baxter KA, Askew DA, et al. Model of care for the management of complex Type 2 diabetes managed in the community by primary care physicians with specialist support: an open controlled trial. Diabet Med. 2013;30:1112-21. 19. Chopra I, Kamal KM. Variations in blood pressure and lipid goal attainment in primary care. Curr Med Res Opin. 2013;29:1115-25. 20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;16:461-70. 21. Gaede P, Tarnow L, Vedel P, Parving HH, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbumuminuria. Nephrol Dial Transplant. 2004;19:2784-88. 22. Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54:32-43. 23. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014;63(2)(S2):S3-21. 24. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641-50. 25. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical implications and limitations J Am Soc Nephrol. 2004;16:3027-37. 26. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and over nephropathy. Ann Intern Med. 2003;138:542-9. 27. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498-509. 28. Thompson CF, Simmons D, Collins JF, Cecil A. Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus. Diabetic Medicine. 2001;18:40-6. 29. Leehey DJ, Kramer HJ, Daud TM, et al. Progression of kidney diseases in type 2 diabetes - beyond blood pressure control: an observational study. BMC Nephrol. 2005;6:8. 30. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282-7. 31. Poggio ED, Wang X, Greene T, et al. Performance of modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol. 2005;16:459-66. 2ff7e9595c
Comments